Antifungal agent 180

Antifungal agent 180 (compound L22) exhibits potent and broad-spectrum in vitro antifungal activity against nine plant pathogenic fungi, with the strongest inhibitory effect against Botrytis cinerea (92.7% at 50 μg/mL); and it shows highly effective inhibition against Verticillium dahliae (EC₅₀ = 5.72 μg/mL) and Magnaporthe grisea (EC₅₀ = 5.96 μg/mL)^[1].
Antifungal agent 180 increases the cell membrane permeability of Magnaporthe grisea and induces cytoplasmic leakage of nucleic acids and proteins^[1].
Antifungal agent 180 (50-100 μg/mL) causes catastrophic structural damage to Magnaporthe grisea hyphae, including surface collapse, cytoplasmic disintegration, and impaired membrane integrity^[1].
Antifungal agent 180 (50‑100 μg/mL) results in extensive transcriptional changes and proteomic alterations in Magnaporthe grisea, including downregulation of ergosterol biosynthesis and upregulation of stress response genes; furthermore, at the regulatory level, it disrupts sterol homeostasis, induces oxidative imbalance accompanied by lipid peroxidation, and leads to compensatory metabolic reprogramming^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.